Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas
-
- Eve Maubec
- Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
-
- Marouane Boubaya
- Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
-
- Peter Petrow
- Association de Cabinet de Radiologie et d’Imagérie Médicale, Service de Radiologie, Polyclinique Saint-Côme, Compiègne, France
-
- Marie Beylot-Barry
- Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
-
- Nicole Basset-Seguin
- Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
-
- Lydia Deschamps
- Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris, France
-
- Jean-Jacques Grob
- Hôpital de la Timone, Marseille, France
-
- Brigitte Dréno
- Service Oncodermatologie, Centre Hospitalier Universitaire Nantes, Centre d’Investigation Clinique 1413, Centre de Recherche en Cancérologie et Immunologie Nantes Angers, Université de Nantes, Nantes, France
-
- Isabelle Scheer-Senyarich
- Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
-
- Coralie Bloch-Queyrat
- Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
-
- Marie-Thérèse Leccia
- Centre Hospitalier Universitaire de Grenoble, Genoble, France
-
- Andreea Stefan
- Centre Hospitalier Universitaire de Caen, Caen, France
-
- Philippe Saiag
- Assistance Publique–Hôpitaux de Paris, Hôpital Ambroise-Paré, Boulogne, France
-
- Florent Grange
- Centre Hospitalier Universitaire Reims, Hôpital Robert-Debré, Reims, France
-
- Nicolas Meyer
- Institut Universitaire du Cancer and Centre Hospitalier Universitaire de Toulouse, Toulouse, France
-
- Julie de Quatrebarbes
- Centre Hospitalier Genevois, Pringy, France
-
- Monica Dinulescu
- Centre Eugène-Marquis, Rennes, France
-
- Delphine Legoupil
- Centre Hospitalier Régional Universitaire de Brest, Brest, France
-
- Laurent Machet
- Centre Hospitalier Régional Universitaire de Tours, Chambray-les-Tours, France
-
- Olivier Dereure
- Université de Montpellier, Montpellier, France
-
- Ouidad Zehou
- Assistance Publique–Hôpitaux de Paris, Hôpital Henri-Mondor, Créteil, France
-
- Henri Montaudié
- Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Nice, France
-
- Ewa Wierzbicka-Hainaut
- Centre Hospitalier Universitaire La Milétrie, Poitiers, France
-
- Yannick Le Corre
- Centre Hospitalier Universitaire d'Angers, Angers, France
-
- Sandrine Mansard
- Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, Clermont-Ferrand, France
-
- Sarah Guégan
- Assistance Publique–Hôpitaux de Paris, Hôpital Cochin, Paris, France
-
- Jean-Philippe Arnault
- Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France
-
- Sophie Dalac
- Centre Hospitalier Universitaire de Dijon, Dijon, France
-
- François Aubin
- Centre Hospitalier Régional Universitaire Besançon, France
-
- Céline Alloux
- Assistance Publique–Hôpitaux de Paris, Agence Générale des Equipements et Produits de Santé, Paris, France
-
- Isabelle Lopez
- Association de Cabinet de Radiologie et d’Imagérie Médicale, Service de Radiologie, Polyclinique Saint-Côme, Compiègne, France
-
- Soufian Cherbal
- Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
-
- Annick Tibi
- Assistance Publique–Hôpitaux de Paris, Agence Générale des Equipements et Produits de Santé, Paris, France
-
- Vincent Lévy
- Assistance Publique–Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
抄録
<jats:sec><jats:title>PURPOSE</jats:title><jats:p> To evaluate first-line pembrolizumab monotherapy efficacy and safety in patients with unresectable cutaneous squamous cell carcinomas (CSCCs). </jats:p></jats:sec><jats:sec><jats:title>PATIENTS AND METHODS</jats:title><jats:p> Patients, predominantly men, with their CSSCs’ immunohistochemically determined programmed cell death-ligand 1 (PD-L1) status determined (tumor proportion score threshold, 1%), received pembrolizumab (200 mg every 3 weeks). The primary endpoint was the 39-patient primary cohort’s objective response rate at week 15 (ORR<jats:sub>W15</jats:sub>). Secondary objectives were best ORR, overall survival (OS), progression-free survival (PFS), duration of response (DOR), safety, ORR according to PD-L1 status and health-related quality of life using Functional Assessment of Cancer Therapy–General (FACT-G) score. An 18-patient expansion cohort, recruited to power the study to evaluate the ORR<jats:sub>W15</jats:sub> difference between PD-L1+ and PD-L1– patients, was assessed for ORR, disease control rate, and safety, but not survival. </jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p> Median age of all patients was 79 years. The primary cohort’s ORR<jats:sub>W15</jats:sub> was 41% (95% CI, 26% to 58%), including 13 partial and 3 complete responses. Best responses were 8 partial and 8 complete responses. At a median follow-up of 22.4 months, respective median PFS, DOR, and OS were 6.7 months, not reached, and 25.3 months, respectively. Pembrolizumab-related adverse events affected 71% of the patients, and 4 (7%) were grade ≥ 3. One death was related to rapid CSCC progression; another resulted from a fatal second aggressive head and neck squamous cell carcinoma diagnosed 15 weeks postinclusion. ORR<jats:sub>W15</jats:sub> for the entire population was 42%; it was significantly higher for PD-L1+ patients (55%) versus PD-L1– patients (17%; P = .02). Responders’ W15 total FACT-G score had improved ( P = .025) compared with nonresponders. </jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p> First-line pembrolizumab monotherapy exhibited promising anti-CSCC activity, with durable responses and manageable safety. PD-L1 positivity appears to be predictive of pembrolizumab efficacy. </jats:p></jats:sec>
収録刊行物
-
- Journal of Clinical Oncology
-
Journal of Clinical Oncology 38 (26), 3051-3061, 2020-09-10
American Society of Clinical Oncology (ASCO)